Herbimycin A
Based on 1 Customer Validation
Herbimycin A is an antibiotic and protein tyrosine kinase inhibitor. Herbimycin A directly inhibits the autophosphorylation of p210 BCR-ABL with an IC50 of approximately 5 μM, and reduces Src kinase activity. Herbimycin A also induces the degradation of receptor tyrosine kinases such as insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (IR) and epidermal growth factor receptor (EGFR) via the ubiquitin-20S proteasome pathway. Herbimycin A directly modifies NF-κB p50, with the main target site involving Cys62, thereby blocking the DNA binding of p50 and NF-κB-driven gene expression. Herbimycin A can be used in studies related to tyrosine kinase signaling, chronic myeloid leukemia, NF-κB signaling, osteoclast function, apoptosis and cellular stress.
For research use only. We do not sell to patients.
- Purity : 99%
- CAS No.: 70563-58-5
- Formula: C30H42N2O9
- Molecular Weight:574.66
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[6]|
p210 BCR-ABL 5 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| K562 | IC50 |
95 nM
|
Growth inhibition activity against human leukemia K562 cells assessed by cell number counting after 4 days of incubation.
Growth inhibition activity against human leukemia K562 cells assessed by cell number counting after 4 days of incubation.
|
2910452 |
| HL-60 | IC50 |
1030 nM
|
Growth inhibition activity against human leukemia HL-60 cells assessed by cell number counting after 4 days of incubation.
Growth inhibition activity against human leukemia HL-60 cells assessed by cell number counting after 4 days of incubation.
|
2910452 |
| THP-1 | IC50 |
1130 nM
|
Growth inhibition activity against human leukemia THP-1 cells assessed by cell number counting after 4 days of incubation.
Growth inhibition activity against human leukemia THP-1 cells assessed by cell number counting after 4 days of incubation.
|
2910452 |
| U-937 | IC50 |
1750 nM
|
Growth inhibition activity against human leukemia U937 cells assessed by cell number counting after 4 days of incubation.
Growth inhibition activity against human leukemia U937 cells assessed by cell number counting after 4 days of incubation.
|
2910452 |
In Vitro
Herbimycin A (10-100 μM; 2 h) directly inhibits the binding of recombinant human NF-κB p50 to the NF-κB consensus DNA sequence, whereas the Cys62→Ser mutant (C62S) is insensitive to Herbimycin A at the tested concentrations, supporting that Herbimycin A inhibits NF-κB DNA binding via modifying p50 Cys62[3].
Herbimycin A (2 μM; 1 h pre-incubation) inhibits IL-1α- or PMA-induced IL-2 production in EL4.NOB-1 cells, reducing IL-1α-induced IL-2 levels from 0.9 ng/mL to <0.1 ng/mL, and decreasing PMA-induced IL-2 levels from 50 ng/mL to 3.25 ng/mL[3].
Herbimycin A (24 h) inhibits insulin-induced tyrosine phosphorylation of IGF-IR, IRS-1 and GAP in serum-starved MCF-7 cells in a dose-dependent manner, and its activity is detectable at a concentration of 17.4 nM after 24 h of pre-incubation[1].
Herbimycin A (0.1-10 μg/mL; 24 h) reduces IGF-IR levels in MCF-7 cells and IR and EGFR levels in MDA-MB-468 cells in a concentration-dependent manner; in MCF-7 cells, Herbimycin A (5 μg/mL) shortens the apparent half-life of IGF-IR from >24 h to approximately 6-7 h, and its degradation can be blocked by 20S proteasome inhibitors[1].
Herbimycin A (up to 1 μg/mL; 16-24 h) reduces foci of Rous sarcoma virus-transformed chicken embryo fibroblasts in a concentration-dependent manner, with complete disappearance of transformed foci at 1 μg/mL; the foci can reappear after the removal of Herbimycin A. It reverses transformation driven by tyrosine kinase oncogenes such as src, yes, fps, ros, abl and erbB, but exerts no similar effect on transformation driven by ras and myc[5].
Herbimycin A (50 nM; 1-3 h) rapidly reduces the tyrosine phosphorylation levels of p210 BCR-ABL and cellular proteins in K562 cells, with approximately 55% reduction in p210 BCR-ABL phosphorylation at 1 h, and tyrosine phosphorylation signals become almost undetectable after 3 h; Herbimycin A also induces erythroid differentiation of K562 cells in a concentration-dependent manner[2].
Herbimycin A (4 d) inhibits the growth of K562 cells with an IC50 of 95 nM; its erythroid differentiation-inducing effect reaches the maximum at 1 × 10-7 M[2].
Herbimycin A (1 μg/mL; 2 h) upregulates the expression of multiple stress proteins in rat embryonic fibroblasts; pre-exposure to Herbimycin A for 2 h followed by an 8 h recovery period enables REF cells to acquire a thermotolerant phenotype and enhances their viability after severe heat stress at 45°C for 45 min[7].
Herbimycin A (1-100 ng/mL) inhibits osteoclastic bone resorption in mouse bone marrow cultures, isolated rat osteoclasts and fetal mouse long bone organ cultures in a concentration-dependent manner; treatment with 100 ng/mL for 24 h also significantly reduces PTH-stimulated pp60c-Src tyrosine kinase activity in mouse bone marrow cells[4].
Herbimycin A (1 μg/mL; 6 h) increases the expression level of the 70-kDa HSP70 to approximately 30 times that of untreated cells, and the induced HSP70 is mainly distributed in the cytoplasm[8].
Herbimycin A inhibits p210 BCR-ABL autophosphorylation in a concentration-dependent manner in cell-free immune complex kinase assays, with an IC50 of approximately 5 μM; the inhibition persists after washing away free Herbimycin A prior to the kinase reaction, supporting its direct action on p210 BCR-ABL[6].
Herbimycin A induces HSP70 in a time- and concentration-dependent manner in A431 human epidermoid carcinoma cells[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:murine EL4.NOB-1 thymoma cells
-
Concentration:0.02-2 μM
-
Incubation Time:1 h (preincubation prior to 24 h IL-1α stimulation)
-
Result:Caused concentration-dependent inhibition of IL-1α-induced IL-2 production.
Reduced IL-2 levels from 0.9 ng/mL to less than 0.1 ng/mL at 2 μM.
-
Cell Line:Recombinant human p50
-
Concentration:10-100 μM
-
Incubation Time:1 h (preincubation prior to 24 h PMA stimulation)
-
Result:Inhibited p50 binding to the NF-κB consensus DNA sequence, whereas the C62S p50 mutant was insensitive.
-
Cell Line:K562
-
Concentration:50 nM
-
Incubation Time:1-3 h
-
Result:Reduced p210 BCR-ABL phosphorylation by approximately 55% at 1 h, and tyrosine phosphorylation was barely detectable after 3 h.
-
Cell Line:NRK-52E
-
Concentration:500 ng/ mL
-
Incubation Time:24 h
-
Result:Reduced okadaic acid-induced apoptosis by approximately 50% and inhibited p38 activation and ATF-2 phosphorylation.
In Vivo
Herbimycin A (100 μg/mouse/injection; i.p.; 2 times/day; 8 d, i.e., 200 μg/mouse/day) begins to reduce blood Ca2+ levels on day 4 in hypercalcemic nude mice bearing human squamous cell carcinoma MH-85, with a significant reduction observed on day 8, but does not affect MH-85 tumor growth[4].
Herbimycin A (2 mL/kg of 1 mg/6 mL solution; i.p.; single administration) induces HSP70 in the liver of male Sprague-Dawley rats, with its expression peaking at 12 h post-administration. When rats are exposed to heat stress at 45°C for 25 min after 12 h, the peak core body temperature of the Herbimycin A group is 41.16°C, which is lower than that of the vehicle group (41.76°C) and the saline group (41.85°C). Additionally, Herbimycin A significantly reduces TUNEL-positive hepatocyte apoptosis and caspase-3 activation[10].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR Swiss white mice (male, 5-6 weeks old, hypercalcemia induced by subcutaneous recombinant human interleukin-1α injections)[4]
-
Dosage:10 μg/mouse per injection
-
Administration:s.c.; four times a day
-
Result:Markedly prevented the development of recombinant human interleukin-1α-induced hypercalcemia.
Maintained ionized calcium level near baseline by day 4, compared to ≈1.6 mmol/L in interleukin-1α-only treated mice.
-
Animal Model:BALB/c nu/nu nude mice (hypercalcemia induced by subcutaneous MH-85 human squamous cancer inoculation)[4]
-
Dosage:100 μg/mouse per injection; 200 μg/mouse total daily dose
-
Administration:i.p.; twice a day; 8 days
-
Result:Lowered blood ionized calcium levels by day 4, with a significant decrease to ≈1.55 mmol/L observed by day 8, compared to ≈1.95 mmol/L in DMSO-treated control mice.
Did not affect MH-85 tumor growth.
-
Animal Model:Sprague-Dawley (male, 250-300 g)[10]
-
Dosage:2 mL/kg of 1 mg/6 mL solution
-
Administration:i.p.; single dose
-
Result:Induced liver hsp70 expression to peak levels (35 arbitrary % volume) at 12 h post-administration, with expression significantly higher than at 6, 18, and 24 h.
Induced 20 arbitrary % volume of hsp70 in liver at 12 h post-administration, which was higher than levels in vehicle- and saline-treated rats.
Reduced peak core temperature to 41.16 °C during heat stress, lower than the peak temperatures of vehicle- and saline-treated rats.
Decreased the percentage of apoptotic hepatocytes significantly compared to vehicle- and saline-treated rats.
Increased levels of procaspase-3 (32 kDa) and decreased levels of active caspase-3 (20 kDa) in liver tissue compared to vehicle- and saline-treated rats.
Chemical Information
-
CAS No. 70563-58-5
-
Appearance Solid
-
Molecular Weight 574.66
-
Formula C30H42N2O9
-
Color Light yellow to yellow
-
SMILES
CO[C@H]([C@H](C[C@@H]([C@@H]([C@H](/C=C([C@@H]1OC(N)=O)\C)C)OC)OC)C)C(C(C(NC(/C(C)=C/C=C\[C@@H]1OC)=O)=C2)=O)=CC2=O
-
Structure Classification
-
Initial Source
Streptomyces spp.
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 1 mg/mL (1.74 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Protocol for Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay detects protein-nucleic acid binding by incubating a labeled DNA or RNA probe with purified protein or cell extract, then separating free probe from slower-migrating protein-probe complexes on a native gel. For cancer cells, primary neurons, mouse tumor samples, intestinal organoids, inflammatory macrophages, or drug-treated samples, EMSA can measure transcription-factor DNA binding or RNA-binding protein activity in extracts, but it does not directly measure transcription, protein expression, or chromatin occupancy in intact cells. Specificity is judged by competition with unlabeled wild-type probe, failure of mutated or unrelated competitors to compete, and antibody supershift or disruption when the binding protein identity must be confirmed.
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Purity & Documentation
-
Data Sheet (308 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7402 mL | 8.7008 mL | 17.4016 mL | 43.5040 mL |